Industry and US FDA officials likely will meet for months to hammer out the agreements needed to reauthorize the three user fee programs. • Source: Pink Sheet illustration
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
